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Abstract
Background: Folic acid is widely used to lower homocysteine concentrations and prevent adverse cardiovascular outcomes.
However, the effect of folic acid on cardiovascular events is not clear at the present time. We carried out a comprehensive
systematic review and meta-analysis to assess the effects of folic acid supplementation on cardiovascular outcomes.
Methodology and Principal Findings: We systematically searched Medline, EmBase, the Cochrane Central Register of
Controlled Trials, reference lists of articles, and proceedings of major meetings for relevant literature. We included
randomized placebo-controlled trials that reported on the effects of folic acid on cardiovascular events compared to
placebo. Of 1594 identified studies, we included 16 trials reporting data on 44841 patients. These studies reported 8238
major cardiovascular events, 2001 strokes, 2917 myocardial infarctions, and 6314 deaths. Folic acid supplementation as
compared to placebo had no effect on major cardiovascular events (RR, 0.98; 95% CI, 0.93–1.04), stroke (RR, 0.89; 95%
CI,0.78–1.01), myocardial infarction (RR, 1.00; 95% CI, 0.93–1.07), or deaths from any cause (RR, 1.00;95% CI, 0.96–1.05).
Moreover, folic acid as compared to placebo also had no effect on the following secondary outcomes: risk of
revascularization (RR, 1.05; 95%CI, 0.95–1.16), acute coronary syndrome (RR, 1.06; 95%CI, 0.97–1.15), cancer (RR, 1.08; 95%CI,
0.98–1.21), vascular death (RR, 0.94; 95%CI,0.88–1.02), or non-vascular death (RR, 1.06; 95%CI, 0.97–1.15).
Conclusion/Significance: Folic acid supplementation does not effect on the incidence of major cardiovascular events,
stroke, myocardial infarction or all cause mortality.
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Introduction
Cardiovascular disease is the leading cause of premature
morbidity and mortality worldwide for both men and women
[1,2]. Over the past few decades, many studies have shown a
strong correlation between hyperhomocysteinemia and vascular
disease [3–6], and identified elevated homocysteine levels as a risk
factor for coronary artery disease, stroke, and deep vein
thrombosis. Therefore, it has been suggested that raised
concentrations of homocysteine in the blood should be lowered
as a therapeutic approach to prevent cardiovascular disease [7,8].
However, reduction of the concentrations of homocysteine in the
blood has not consistently been shown to be beneficial [9–11].
Currently, folic acid and B vitamins are used for achieving
target homocysteine levels, and are clearly effective at reducing
concentrations of plasma homocysteine. However, their effects on
vascular events remain unclear [12]. Additionally, several large-
scale randomized controlled trials have shown that reducing the
extent of homocysteinemia with folic acid does not improve
cardiovascular outcomes. When combined with B vitamins, folic
acid may actually accelerate the risk of cardiovascular disease, and
this has further restricted its application in clinical prevention [13].
Recently, additional large-scale randomized controlled trials of
folic acid therapy combined with other B vitamins have been
completed [11,14,15]. A number of these trials indicated that
combination therapy had some beneficial effect on cardiovascular
events, whereas others showed that it had limited effects, and some
even found that it could induce drug-related adverse reactions.
This led to uncertainty over the presence and magnitude of any
protective cardiovascular effects of folic acid and difficulties in
interpretation of the results. For a better understanding of the
effect of folic acid on homocysteine levels and cardiovascular
outcomes, data from these recent trials need to be re-evaluated
and combined with the data in former literature on folic acid.
Therefore, we carried out a systematic review and meta-analysis of
pooled data from randomized controlled trials to assess the
possible effect of folic acid supplementation on major cardiovas-
cular events.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25142Methods
Data sources, search strategy, and selection criteria
Randomized, double-blind, placebo-controlled, and trials of
folic acid therapy in English-language literature were eligible for
inclusion in our meta-analysis, regardless of publication status
(published, unpublished, in press, and in progress), and the effects
on homocysteine levels and cardiovascular outcomes were
examined. Relevant trials were identified with the following
procedure:
(1) Electronic searches. We searched the electronic
databases Medline, EmBase, and the Cochrane Central Register
of Controlled Trials for articles to a time limit of Nov. 20, 2010,
using ‘‘folic acid’’, ‘‘folate’’, ‘‘cardiovascular disease’’, ‘‘coronary
disease’’, ‘‘coronary thrombosis’’, ‘‘ischemic heart disease’’,
‘‘stroke’’, ‘‘coronary stenosis’’, ‘‘coronary restenosis’’, and
‘‘randomized controlled trial’’ as the search terms. All reference
lists from reports on non-randomized controlled trials were
searched manually for additional eligible studies.
(2) Other sources. We contacted authors to obtain any
possible additional published or unpublished data, and searched
the proceedings of annual meetings in the Cochrane
Cardiovascular Disease Group Specialized Register. In addition,
we searched for ongoing randomized controlled trials, which had
been registered as completed but not yet published, in the
metaRegister of Controlled Trials. Medical subject headings and
methods, patient population, and intervention were used to
identify relevant trials. This review was conducted and reported
according to the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analysis) Statement issued in
2009 (Checklist S1) [16].
The literature search was undertaken independently by 2
authors (Chao Wang and Ying-Yi. Qin) with a standardized
approach, and any disagreement between these 2 authors was
settled by a third author (Yu-Hao. Zhou) until a consensus was
reached. All completed randomized controlled trials assessing the
effects of folic acid therapy compared with the effects of a placebo,
and reporting at least 1 outcome of major cardiovascular events
were included as eligible trials. Randomized controlled trials to be
included in the analysis were limited to those with at least 100
patients and at least 6 months follow-up, to ensure that only high-
quality studies were incorporated.
Data collection and quality assessment
Two investigators (Chun-Fang. Wu and Mei-Jing. Wu)
independently extracted and collected data using a standardized
data-extraction protocol. Any discrepancy was settled by group
discussion, after which the primary authors (Yu-Hao. Zhou and Jia
He) made the final decision. The data collected included baseline
patient characteristics (number of patients, age, sex, pre-existing
diseases, interventions, total plasma homocysteine, and duration of
follow-up). The outcomes investigated included major cardiovas-
cular events, stroke, myocardial infarction, total mortality, and
possible drug-correlated adverse reactions. We measured the
quality of the trials included in this study with the Jadad score [17]
on the basis of randomization, concealment of treatment
allocation, blinding, completeness of follow-up, and use of
intention-to-treat analysis.
Statistical analysis
We assessed the overall effect of folic acid supplementation on
all data from the included trials. The outcomes were reported
using relative risks (RR) with 95% confidence intervals (CIs) to
estimate the effect of folic acid on major cardiovascular events,
stroke, myocardial infarction, total mortality, and possible drug-
correlated adverse reactions. After this, a subgroup analysis was
carried out based on the number of patients, duration of folic acid
supplementation, mean age, baseline total plasma homocysteine,
pre-existing disease, and Jadad score. The statistical estimates of
effect were derived using a random-effects model with Mantel–
Haenszel statistics. Heterogeneity of treatment effects between
studies was investigated visually by scatter plot analysis and
statistically by the heterogeneity I
2 statistic. I
2 statistic of 0%–40%
indicates unimportant heterogeneity, 30%–60% indicates moder-
ate heterogeneity, 50%–90% indicates substantial heterogeneity,
and 75%–100% indicates considerable heterogeneity [18]. P
values were calculated by x
2 tests. All the reported P values are
two-sided and value of P less than 0.05 was regarded as statistically
significant for all included studies. All analyses were calculated
using STATA (version 10.0).
Results
We identified 1594 potentially relevant trials from our initial
electronic search, and excluded 1528 trials after a preliminary
review. The remaining 66 studies were retrieved for detailed
assessment, and 16 randomized controlled trials met the inclusion
criteria (Figure 1 and Protocol S1 [16]), which consisted of data of
44841 individual patients. Table 1 summarized the baseline
characteristics of the participants and the design of the studies
included. The trials included in this study compared folic acid
supplementation (with or without B vitamins) with placebo. The
follow-up for patients ranged from 8.3 to 87.6 months, with a
mean of 43.2 months. The population of the trials ranged from
114 to 12064 individuals, with a mean of 2803. We restricted the
inclusion criteria to randomized placebo-controlled trials with at
least 100 patients and a minimum of 6 months follow-up to ensure
that high-quality literature was included in our research, and to
ensure a reliable conclusion. One trial had a Jadad score of 5, 6
trials had a score of 4, 7 trials had a score of 3, and the remaining 2
trials had a score of 2.
Data for the effect of folic acid on major cardiovascular events
were available from 12 trials, including 38015 individuals with
8238 cardiovascular events. Figure 2 shows the effect of folic acid
(with or without B vitamins) on major cardiovascular events as
compared to placebo. The pooled RR showed a 2% reduction in
cardiovascular event rates, and with no evidence showed that folic
acid therapy protected against cardiovascular event risk (RR, 0.98;
95%CI, 0.93–1.04). Although there was some evidence of
heterogeneity across the studies included, a sensitivity analysis
indicated that the results were not affected by sequential exclusion
of any particular trial from all pooled analysis.
Data for the effect of folic acid on stroke were available from 12
trials, including 42960 participants with 2001 events of stroke.
Overall, folic acid therapy reduced the risk of stroke by 11%, but
was not associated with a statistically significant decrease in the
risk of stroke (fatal or nonfatal) events (RR, 0.89; 95% CI, 0.78–
1.01, with unimportant heterogeneity, Figure 3).
Data for the effect of folic acid on myocardial infarction were
available from 11 trials, including 39923 patients and 2917 events
of myocardial infarction. No effect of folic acid therapy on the risk
of myocardial infarction events was observed (RR, 1.00; 95% CI,
0.93–1.07, without evidence of heterogeneity of effect, Figure 4).
Fourteen trials including 44340 patients and 6314 total events of
mortality were recorded, with 10 trials providing separate data for
vascular death and 8 studies providing separate data for non-
vascular death. There was no evidence to show that folic acid
therapy could reduce the risk of mortality, whether total mortality,
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sensitivity analysis, we excluded the (SEARCH) Collaborative
Group study [11]. This trial specifically included individuals with
pre-existing myocardial infarction, which may have contributed to
a high mortality rate. After this, we could conclude that folic acid
therapy was associated with a reduction in the risk of vascular
death, which was decreased by 11% (RR, 0.89; 95% CI, 0.81–
0.98, Figure 5).
Ten of the trials included 38068 patients with 2939 revascu-
larization events. There was no evidence to show that folic acid
therapy protected against revascularization, although heterogene-
ity was observed in the magnitude of the effect across the trials
included (RR, 1.05; 95% CI, 0.95–1.16, Figure 5). However, after
sequential exclusion of each trial from all pooled analysis, the
results were not affected by exclusion of any specific trial.
The risk of coronary syndrome was reported in 5 trials,
including 19050 individuals and 3148 events of coronary
syndrome. No evidence indicated that folic acid therapy protected
against coronary syndrome risk (RR, 1.06; 95%CI, 0.97–1.15,
without evidence of heterogeneity of effect, Figure 5).
Six trials reported data for the incidence of cancer, including
26544 patients and 2472 events of cancer. Reduction in the risk of
cancer with folic acid therapy was not statistically significant (RR,
1.08;95%CI,0.98–1.21,with unimportantheterogeneity,Figure5).
Of the 16 trials included in our meta-analysis, only 2 provided
data about dialysis and amputation, and included 2294 partici-
pants, 725 dialysis events, and 116 amputation events. The pooled
analysis showed no significant differences between folic acid
therapy and placebo therapy for dialysis or amputation (Figure 5).
Subgroup analyses were carried out for major cardiovascular
events, stroke, and myocardial infarction. We noted that folic acid
therapy was associated with a reduction in the risk of major
cardiovascular events, when trials with less than 36 months follow-
up period were included. Furthermore, compared with placebo,
folic acid therapy showed a clear effect on stroke events when the
mean age of the patients was less than 60 years. However, no other
significant differences were identified between the effect of folic
acid therapy and placebo, based on additional subset factors
(Figure 6).
Discussion
This large quantitative review included 44841 individuals in 16
trials with a broad range of baseline characteristics. The results of
our meta-analysis suggest that folic acid therapy does not effect on
the incidence of major cardiovascular events, stroke, myocardial
infarction, all cause mortality or other cardiovascular-related
outcomes.
Figure 1. Flow diagram of the literature search and trial selection process.
doi:10.1371/journal.pone.0025142.g001
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cular disease was described initially by observational studies, which
may overestimate the effect of this relationship. Two meta-analyses
of epidemiologic studies [4,31] suggested that reduced homocys-
teine levels could lower the risk of coronary heart disease, stroke,
and cardiovascular disease. However, Bazzano et al [32]
concluded that folic acid therapy did not significantly contribute
to cardiovascular disease, stroke, or myocardial infarction.
Therefore, we carried out a systematic review and meta-analysis
to explain the possible effect of folic acid on major cardiovascular
events, and possible drug-correlated adverse reactions. This study
was based on randomized controlled trials and explored any
possible correlation between folic acid supplementation and the
outcomes of any cardiovascular-related disease.
Table 1. Design and patient characteristics for trials included in the systematic review and meta-analysis.
Source
No. of
patients
Mean
age, y
Sex
(male)
Pre-existent
diseases Intervention
Total homocysteine
(mmol/L)
Duration of
follow-up (months)
Jadad
score
Andrew A.H [14] (2010) 238 60.4 178 (74.79%) Diabetic
nephropathy
2.5 mg folic acid 15.55 36 5
VITATOPS Study
[15] (2010)
8164 62.6 5218 (63.91%) Stroke 2 mg folic acid 14.3 40.8 4
Howard N.H [18] (2009) 506 61.4 309 (61.07%) tHcy $8.5 mmol/L 5 mg folic acid 9.6 37.2 3
Marta E [19] (2008) 2319 61.7 1840 (79.34%) CHD 0.8 mg folic acid 14.4 38 4
Christine M.A [20] (2008) 5442 62.8 0 (0%) CHD 2.5 mg folic acid NR 87.6 3
Jamison R.L [10] (2007) 2056 65.8 2023 (98.39%) ACKD or ESRD 40 mg folic acid 22.4 38.4 3
Areuza V.A.V [21] (2007) 186 48.5 110 (59.14%) ESKD 10 mg folic acid,
3 times a week
24.7 24 3
Bonaa K.H [22] (2006) 2815 63.0 2085 (74.07%) CHD 0.8 mg folic acid 13.1 42 4
HOPE-2 Study [23] (2006) 5522 68.9 3963 (71.77%) CHD 2.5 mg folic acid 12.2 60 4
ASFAST Study [24] (2006) 315 56.0 213 (67.62%) CRF 15 mg folic acid 27.0 43.2 3
The Swiss Heart Study
[25] (2002)
553 62.5 445 (80.47%) Coronary
stenosis
1 mg folic acid NR 12 3
Mark S.D [26] (1995) 3318 54.0 1461 (44.03%) Esophageal
Dysplasia
0.8 mg folic acid NR 72 2
Liem A [27] (2005) 593 65.2 462 (77.91%) CHD 0.5 mg folic acid 12.1 42 2
SEARCH Collaborative
Group [11] (2010)
12064 NR 10012 (82.99%) MI 2 mg folic acid 13.5 80.4 4
Marco R [28] (2006) 114 64.4 63 (55.26%) Hemodialysis 5 mg folic acid 31.7 29 4
Lange H [29] (2004) 636 61.3 490 (77.04%) Coronary stenting 1 mg folic acid 12.6 8.3 3
doi:10.1371/journal.pone.0025142.t001
Figure 2. Effects of folic acid supplementation on the risk of major cardiovascular events.
doi:10.1371/journal.pone.0025142.g002
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epidemiologic research [4,31], and also support the conclusion
made by Bazzano et al [32] that folic acid had no significant
benefit or adverse effect on the risk of major cardiovascular events,
stroke, myocardial infarction, or any other related disease.
No significant differences in the relative risk of cardiovascular
disease were reported across a wide background of cardiovascular
risk in these trials. In our meta-analysis, participants with a history
of cardiovascular disease or stroke [11,15,20,21,23,24,28], end-
stage renal disease [10,22,29], chronic renal failure [25], diabetic
Figure 3. Effects of folic acid supplementation on the risk of stroke.
doi:10.1371/journal.pone.0025142.g003
Figure 4. Effects of folic acid supplementation on the risk of myocardial infarction.
doi:10.1371/journal.pone.0025142.g004
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[27], and hyperhomocysteinemia [19] were included. However, an
unimportant heterogeneity was reported for the included trials.
Another important factor that may have affected the results is the
plasma homocysteine levels. Subgroup analysis (Figure 6), based
on baseline plasma homocysteine levels, was used to explore any
possible variations. The reason for the absence of an effect of folic
acid could be that the extent of the reduction in homocysteine was
not reported in many trials, thus we were unable to assess the
correlation between the level of reduction in homocysteine and
cardiovascular outcomes.
There were no significant differences between folic acid
supplementation and placebo in the relative risk for major
cardiovascular events, myocardial infarction, or stroke. The
reason for this could be that although elevated homocysteine
levels impair vascular function, the impact of homocysteine on
vascular outcomes is not primarily related to the pathogenesis of
coronary artery disease [33,34], which is largely attributable to
plaque formation and rupture. Furthermore, high doses of B6
vitamins may adversely affect vascular remodeling and myocardial
repair, and may therefore play an important role in increasing the
rates of complications and death among patients with cardiovas-
Figure 5. Summary of the relative risks of all outcomes assessed.
doi:10.1371/journal.pone.0025142.g005
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[34,35]. Therefore, although folic acid may have direct beneficial
effects on cardiovascular outcomes in patients, these effects may be
reduced or balanced by the adverse effects of high doses.
Folic acid supplementation may play an important role in
carcinogenesis, because when it is administered to individuals with
established cancers, it potentially promotes tumor growth [36,37].
It has also been reported that the introduction of folic acid may
increase the risk of colorectal cancer [38]. According to our
review, folic acid therapy resulted in an 8% increase in the risk of
cancer, although this difference was not statistically significant.
The reason for this increase in carcinogenesis can be explained by
the fact that folic acid supplementation may affect endothelial
function and support cell growth through mechanisms indepen-
dent of homocysteine [39].
Importantly, folic acid and B vitamins are water-soluble and
excreted by the kidney; therefore, therapy toxicity may be of great
concern in patients with impaired renal function. In patients with
end-stage renal failure who have hyperhomocysteinemia wherein
homocysteine levels must be reduced, alternative, non-vitamin
therapies are important. For example, enhancing urinary
excretion can help to avoid a decrease in glomerular filtration
rate and an increase in major cardiovascular events [35,40].
A previous meta-analysis [32] has illustrated that the risk of
cardiovascular outcomes is not significantly reduced using folic
acid supplementation compared with placebo; this conclusion was
similar to our current meta-analysis. In our research, subgroup
analysis suggested that folic acid supplementation contributes to a
causal relationship with the risk of major cardiovascular events
and stroke; however, these conclusions may be unreliable, because
a smaller number of trials were included in such subsets. In
addition, we did not include small trials with less than 100 patients
and 6 months follow-up to ensure that the quality of studies
included were comparable to that of a study by Bazzano et al [32].
Finally, the initial evidence for a correlation between folic acid
supplementation and cardiovascular disease was provided by
observational studies, which may overestimate the size of the
effect. Our meta-analysis was restricted to randomized controlled
trials to meet our inclusion criteria and aimed to provide the best
evidence for a causal relationship.
The limitations of our research are as follows: (i) The extent of
homocysteine lowering was unclear owing to the lack of data, and
therefore, we were unable to explore the association between the
levels of homocysteine and cardiovascular events. (ii) Although
subgroup analysis suggested that folic acid supplementation
significantly reduced the risk of major cardiovascular events for
patients with follow-up of less than 36 months or decreased the risk
of stroke for those patients with a mean age of less than 60 years,
these results may be variable because of the small number of trials
that were included in such subsets. (iii) Inherent assumptions made
for any meta-analysis, because the analysis used pooled data either
published or provided by individual study authors, and individual
patient data or original data were unavailable, which restricted us
doing more detailed relevant analysis and obtaining more
comprehensive results.
The findings of this study suggested that folic acid supplemen-
tation had no significant effects on major cardiovascular events,
stroke, myocardial infarction or all cause mortality . Furthermore,
high-doses folic acid supplementation may increase the risk of
cancer cell growth [36] and impair renal function [35]. Therefore,
in future research, it is important to focus on healthy individuals
for primary prevention of cardiovascular disease, and to combine
other homocysteine-lowering drugs to provide an optimal therapy
that minimizes adverse effects in patients with hyperhomocystei-
nemia. We suggest that the ongoing trials be improved in the
following ways: (i) The adverse effects in clinical trials should be
recorded and reported normatively, so that the side-effects of any
treatment can be evaluated in future trials. ii) The role of
treatment duration and dosage should be investigated in more
detail to explore optimal dose and duration of treatment.
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